Table 3 Patient characteristics for Figure 9

From: TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation

Code assigned (AF)

Sex

Age (years)

Diagnosis

Date of diagnosis

Duration of IBD (years)

Medication

CD01

F

42

CD active

1981

27

Asacolon 400 mg t.d.s.

CD02

F

41

CD active

2002

7

Pentasa; Calcichew; Fosamax; Budesonide

CD03

M

21

CD active

2006

3

Budesonide; Prednisolone; Pentasa 1 g q.d.s.; symbicort inh

CD04

F

44

CD active

1997

12

Clonfolic (?)

CD05

F

30

CD active

2007

2

Asacolon 1.2 g b.d.; Mercaptopurine 50 mg; Ursofalk 1 g

CD06

F

52

CD active

>Decade

5

Topical steroids (foam enemas) only. Never received anti-TNF

CD07

F

24

CD active

2009

8 mo

6-Mercaptopurine 50 mg p.o. o.d.; mesalazine 1.5 g b.d.; Nexium p.r.n.

CD08

F

35

CD active

2006

3

Budesonide 6 mg o.d.; Nexium 40 mg; Questrum one sachet o.d.; Motilium

CD09

F

24

CD active

1999

10

Adalumimab; Asacolon; Calcium; Folate; Implenit

CD10

F

21

CD active

2009

2 mo

Eltroxin 100 mg p.o. o.d.; Budesonide 6 mg p.o. o.d.; Calcichew

CD11

F

53

CD active

1998

11

Salofalk enemas, other medications unknown

CD12

M

22

CD active

2005

>10

Humira (anti-TNF) alt. week, relapsing disease despite treatment

CD13

M

40

CD active

1991

17

6MP 100 mg daily, Asacolon 1.6 g b.d., Nexium 40 mg o.d., Calcichew tabs 2 daily, Infliximab infusion every 4 weeks, relapsing disease despite the treatment

  1. Abbreviations: b.d., twice a day; CD, Crohn’s disease; CRP, C-reactive protein; IBD, inflammatory bowel disease; mo, months; MP, methylprednisolone; o.d., once a day; p.o., per os; p.r.n., as many patients take them; q.d.s., four times a day; t.d.s., three times a day; TNF, tumor necrosis factor.
  2. Bold represents patients on anti-TNFs.
PowerPoint slide
Back to article page